United States Drug Patent 5,780,485: Scope, Claims, Expiration, and Patent Landscape

US Patent No. 5,780,485 is a method-of-use patent covering treatment of benign prostatic hyperplasia and inhibition of prostatic tissue contraction with antagonists showing specified receptor-selectivity ratios. The patent does not claim a defined chemical structure, dosage form, dose, salt, polymorph, formulation, or manufacturing process. Its enforceability ended when the patent term expired, making it a historical blocking patent rather than a current U.S. exclusivity barrier.

The core limitation is functional: the antagonist must bind to the human α1C adrenergic receptor at materially higher affinity than specified comparator receptors, ion channels, or other targets. The broadest independent claims require at least a 48-fold or 26-fold α1C-over-α1B affinity differential. The patent therefore targeted highly α1C-selective adrenergic antagonists rather than conventional nonselective α1 blockers.

What does US Patent 5,780,485 protect?

The patent protects two related therapeutic concepts:

Treating benign prostatic hyperplasia in a subject.
Inhibiting contraction of prostatic tissue by contacting prostate tissue with the antagonist.

Claims 1 through 28 cover treatment of BPH. Claims 29 through 56 cover inhibition of prostatic tissue contraction. The two claim groups substantially duplicate each other, with the principal difference being the claimed therapeutic act.

Claim group	Protected activity	Core selectivity requirement
Claims 1-28	Treating BPH	α1C affinity at least 48-fold or 26-fold higher than α1B affinity, depending on claim
Claims 29-56	Inhibiting contraction of prostatic tissue	Same α1C selectivity thresholds
Claims 8, 36	Higher α1C-over-α1B selectivity	At least 200-fold
Claims 13, 41	Combined α1C-over-α1A and α1C-over-H1 selectivity	At least 35-fold and 417-fold
Claims 18-20, 46-48	Multi-receptor selectivity profiles	Ratios against α1A, α1B, H1, α2 and other targets

The patent is a genus claim set. It is not limited to a named active ingredient. Any antagonist satisfying the claimed receptor-binding ratios and the therapeutic-use limitation could fall within the literal scope, subject to proof of the relevant affinity measurements.

How do the receptor-affinity limitations work?

The claims use relative binding affinity rather than an absolute potency threshold. In practical terms, the relevant comparison is generally expressed as:

[ \text{Selectivity ratio} = \frac{\text{affinity for human α1C receptor}}{\text{affinity for comparator target}} ]

Because binding affinity is commonly reported through inhibition constants such as Ki, the numerical relationship may be expressed inversely depending on the assay convention. A lower Ki ordinarily indicates stronger binding. The patent’s claim language must therefore be interpreted with the patent specification and assay methodology, not by treating the word “affinity” as an unqualified numerical variable.

The principal thresholds are:

Comparator	Lowest expressly claimed α1C selectivity threshold
Human α1B adrenergic receptor	26-fold in claims 10 and 38
Human α1B adrenergic receptor	48-fold in claims 1 and 29
Human α1B adrenergic receptor	200-fold in claims 8 and 36
Human α1A adrenergic receptor	35-fold in claims 13 and 41
Human histamine H1 receptor	10-fold in dependent claims; up to 417-fold in claims 13 and 41
Human α2 adrenergic receptor	28-fold in claims 17 and 45; up to 871-fold in claims 20 and 48
Calcium channel	10-fold in claims 4 and 32; up to 550-fold in claims 22 and 50
Human serotonin receptor	10-fold in claims 6 and 34; up to 74-fold in claims 28 and 56
Human histamine H2 receptor	25-fold in claims 23 and 51; up to 324-fold in claims 25 and 53

The claims also require administration of a “therapeutically effective amount” or, for the tissue claims, an “effective contraction-inhibiting amount.” That limitation prevents the claims from covering mere possession, synthesis, or in vitro binding of an antagonist without the claimed therapeutic or tissue effect.

Which claims are broadest?

Claims 1, 10, 29, and 38 are the broadest independent method claims.

Claim 1 requires:

Treatment of BPH;
Administration of a therapeutically effective amount;
An antagonist binding to human α1C;
At least 48-fold higher α1C affinity than α1B affinity.

Claim 10 reduces the α1C-over-α1B threshold to 26-fold. On its face, claim 10 is broader than claim 1 with respect to the α1B selectivity ratio, assuming the claims otherwise have the same scope.

Claim 29 mirrors claim 1 but covers inhibition of prostatic tissue contraction.

Claim 38 mirrors claim 10 but covers inhibition of prostatic tissue contraction.

The dependent claims narrow the independent claims by adding receptor-selectivity ratios. Examples include:

Claim 8: at least 200-fold α1C-over-α1B selectivity.
Claim 13: at least 35-fold α1C-over-α1A and at least 417-fold α1C-over-H1 selectivity.
Claim 18: at least 91-fold α1C-over-α1A, 65-fold α1C-over-H1, and 229-fold α1C-over-α2 selectivity.
Claim 20: at least 776-fold α1C-over-α1A, 200-fold α1C-over-α1B, 51-fold α1C-over-H1, and 871-fold α1C-over-α2 selectivity.

Claims 29 through 56 repeat this architecture for the tissue-contraction method.

Does the patent cover a particular drug?

No chemical compound is identified in the claims provided. The patent claims an antagonist by receptor-binding profile, not by molecular name or structural formula.

A drug can therefore be relevant only if it satisfies both requirements:

It is an antagonist with the claimed α1C selectivity profile.
It is used for BPH treatment or inhibition of prostatic tissue contraction.

A conventional α1 adrenergic antagonist with weaker selectivity may not meet the numerical limitations. Conversely, a structurally unrelated compound could theoretically satisfy the claims if its receptor-binding data meet the specified thresholds.

The patent should not be equated automatically with patents covering tamsulosin, alfuzosin, silodosin, terazosin, doxazosin, or other BPH therapies. Those products have separate compound, formulation, dosage, polymorph, manufacturing, and method-of-use patent histories. The relevant issue is whether a product’s measured receptor profile falls within the US 5,780,485 thresholds.

What formulations are protected by US 5,780,485?

The patent claims provided do not contain formulation limitations. They do not require:

Extended release;
Controlled release;
Oral administration;
A capsule or tablet;
A particular excipient;
A specific salt;
A polymorph;
A particle-size distribution;
A dissolution profile;
A dosage strength;
A dosing interval.

The claims therefore do not independently protect a formulation. A formulation could be relevant only because it delivers an antagonist used in a claimed BPH treatment. Separate formulation patents would be required to protect release technology, dosage form design, or a particular composition.

This distinction matters in generic litigation. A generic applicant could avoid a formulation patent while still potentially implicating an expired method-of-use patent. Conversely, a product could fall within an active formulation patent even though US 5,780,485 has expired.

When did US Patent 5,780,485 lose exclusivity?

US Patent 5,780,485 issued on July 14, 1998. Its ordinary U.S. patent term expired no later than the mid-2010s under the applicable patent-term rules. The patent is expired as of 2026 and cannot create current U.S. patent exclusivity.

Event	Date or status
U.S. patent number	5,780,485
Issue date	July 14, 1998
Patent type	Therapeutic method-of-use patent
Ordinary term	Expired in the mid-2010s
Current status	Expired
Current blocking effect	None as an unexpired U.S. patent

Patent term is governed principally by 35 U.S.C. §154, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory provisions. A precise historical expiration calculation must be made from the USPTO patent-term record. No current extension can revive an expired patent.[2]

The expiration eliminates patent-based launch risk under this patent. It does not eliminate regulatory requirements, product-liability exposure, trade-secret restrictions, or separate unexpired patents held by other parties.

What is the Orange Book status of US 5,780,485?

The claims are method-of-use claims, but patent-number issuance alone does not establish an Orange Book listing. Orange Book listing depends on whether the patent was submitted by the new drug application holder, accepted by FDA, and associated with an approved drug and use code.

US 5,780,485 should not be treated as an active Orange Book barrier merely because it claims BPH treatment. The relevant FDA questions are:

Whether the patent was ever submitted for listing;
Which NDA, if any, was associated with it;
Whether FDA accepted the listing;
What use code was assigned;
Whether the listing was later removed or became expired.

An expired patent cannot support a current Paragraph IV exclusion period or block ANDA approval on its own. Under the Hatch-Waxman framework, Paragraph IV litigation consequences attach to listed patents that remain legally relevant to the drug application.[3]

Were Paragraph IV challenges or generic litigation affected?

The patent’s claim structure could have generated a Paragraph IV issue if it had been listed against an approved BPH product and if a generic applicant’s proposed labeling included the patented use. The most likely legal questions would have been:

Whether the generic product’s active ingredient met the claimed receptor-affinity ratios.
Whether the proposed label induced use for BPH.
Whether the patent was valid under sections 102, 103, 112, and 101.
Whether the patent was enforceable and unexpired.
Whether the claims were properly listed for the relevant approved product.

The claims present several potential litigation pressure points.

Functional genus scope

The patent claims an entire class of antagonists based on receptor selectivity. A challenger could argue that the specification did not demonstrate or enable the full breadth of every claimed numerical ratio across all possible antagonists. Written-description and enablement issues are assessed under 35 U.S.C. §112.[4]

Assay reproducibility

The claims depend on receptor-binding ratios. Differences in receptor constructs, radioligands, membrane preparations, cell systems, assay conditions, and calculation methods could affect the numerical result. A product may therefore require an assay-specific infringement analysis.

Receptor nomenclature

The patent uses α1C and α1A as separate comparators. Modern pharmacology and historical receptor nomenclature are not always identical. Claim interpretation must follow the patent’s specification and prosecution history rather than assuming that current nomenclature maps directly onto the terms used in 1990s-era assays.

Obviousness

A challenger could combine prior-art α1 antagonists, receptor-subtype pharmacology, and BPH treatment disclosures. The central question would be whether the claimed selectivity thresholds and therapeutic application were predictable from the prior art under 35 U.S.C. §103.[5]

How strong is the patent estate?

The standalone estate is weak for current commercial purposes because the patent has expired. Its historical claim breadth was significant, but its business value depended on three facts:

The drug had to meet the specified receptor-binding profile.
The product had to be used for BPH or prostatic contraction.
The patent had to remain unexpired and relevant to the approved product.

The patent has no evident claim coverage for:

Chemical synthesis;
Active pharmaceutical ingredient structure;
Crystalline form;
Salt selection;
Drug product composition;
Extended-release technology;
Manufacturing process;
Stability;
Packaging;
Biomarker selection;
Combination therapy.

That produces a narrow estate around a broad functional therapeutic concept. It could have been commercially important when unexpired, particularly if a marketed antagonist matched the claimed α1C-selectivity profile. It does not provide a surviving platform for current licensing or launch control.

What manufacturing and intellectual-property barriers remain?

US 5,780,485 creates no current manufacturing barrier. A company can manufacture an antagonist without infringing these expired claims.

Current barriers may instead arise from separate rights covering:

The active ingredient;
Process chemistry;
Intermediates;
Crystalline forms;
Drug-device combinations;
Modified-release systems;
Approved labeling;
Trade secrets;
Regulatory exclusivity.

For small-molecule BPH products, biosimilar risk is generally not the relevant framework. Biosimilars are associated with biological products under the Public Health Service Act. Conventional α1 adrenergic antagonists are normally addressed through the ANDA pathway, not a biosimilar application.[6]

How does US 5,780,485 compare with ordinary BPH drug patents?

Patent category	Typical protected subject matter	Relevance of US 5,780,485
Compound patent	Chemical structure and salts	Not covered
Method-of-use patent	Treatment of a disease or symptom	Directly covered
Receptor-selectivity patent	Functional pharmacology	Directly covered
Formulation patent	Release profile and dosage form	Not covered
Polymorph patent	Solid-state form	Not covered
Process patent	Manufacturing route	Not covered
Labeling patent	Specific approved indication or dosing	Partially related, but no dosing limitation is stated
Biologic patent	Sequence, formulation, or manufacturing of biologic	Not relevant

The patent is therefore best classified as a pharmacology-based method patent. Its value was tied to demonstrating that a compound was sufficiently selective for the claimed receptor subtype and that the selectivity produced a BPH-related therapeutic effect.

What generic launch risks exist today?

There is no current U.S. patent launch risk under US 5,780,485 because the patent has expired. A generic or reformulator does not need to design around these claims for current U.S. launch purposes.

Historical launch risk would have depended on:

The product’s α1C/α1B ratio;
The product’s α1C/α1A ratio;
H1, H2, α2, dopamine, serotonin, and calcium-channel binding data;
The ANDA labeling;
Any Orange Book listing;
Whether the patent term remained in force.

A product could have avoided literal infringement by failing to satisfy one required selectivity threshold, but that conclusion would depend on reliable comparative assay data. A product could also have faced induced-infringement allegations if its labeling encouraged the patented BPH use under 35 U.S.C. §271(b).[7]

Key Takeaways

US 5,780,485 is a functional method-of-use patent for BPH treatment and inhibition of prostatic tissue contraction.
The claims require specified α1C receptor-selectivity ratios against α1B, α1A, α2, histamine, dopamine, serotonin, and calcium-channel targets.
The patent does not claim a named compound, chemical structure, formulation, dosage, salt, polymorph, or manufacturing method.
Claims 1, 10, 29, and 38 are the principal broad independent claims.
Claims 29 through 56 largely duplicate claims 1 through 28 for prostatic tissue contraction.
The patent issued July 14, 1998 and expired in the mid-2010s.
It creates no current U.S. patent barrier to generic or branded launch.
Any historical Paragraph IV exposure would have depended on Orange Book listing, product receptor data, labeling, and patent validity.
Biosimilar analysis is generally inapplicable because the patent concerns small-molecule adrenergic antagonists.
Current commercial diligence should focus on separate compound, formulation, polymorph, process, and labeling patents.

FAQs

Does US 5,780,485 cover tamsulosin?

Not automatically. Tamsulosin would be relevant only if its receptor-binding profile satisfied the specific α1C selectivity ratios and its use matched the claims. The patent does not identify tamsulosin by name.

Can an expired method-of-use patent block an ANDA?

No. An expired patent cannot independently prevent approval or commercial launch. A current listed patent, regulatory exclusivity period, or separate unexpired patent could still create a barrier.

Does the patent cover treatment of urinary symptoms generally?

No. The claims are directed to treatment of BPH and inhibition of prostatic tissue contraction. They do not expressly cover every lower urinary tract symptom or every urological indication.

Are receptor-binding assay results enough to prove infringement?

No. Infringement would require proof of every claim limitation, including the therapeutic use and effective amount. The binding assay must also be relevant to the claim construction and the receptor definitions in the patent.

Does the patent protect a once-daily or extended-release BPH formulation?

No. The provided claims contain no release-profile, dosage-form, dosing-frequency, excipient, or formulation limitation.

References

United States Patent and Trademark Office. (1998). U.S. Patent No. 5,780,485.
35 U.S.C. §154. Patent term.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
35 U.S.C. §112. Specification requirements.
35 U.S.C. §103. Conditions for patentability: non-obvious subject matter.
Public Health Service Act, 42 U.S.C. §262. Regulation of biological products.
35 U.S.C. §271. Infringement of patent.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2240495	⤷ Start Trial
Australia	5602994	⤷ Start Trial
Australia	680457	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,780,485

Summary for Patent: 5,780,485